ASX - By Stock
|
NYR |
Re:
CHART
|
|
dsa69
|
146 |
28K |
3 |
14:07 |
14:07 |
ASX - By Stock
|
146
|
28K
|
3
|
|
ASX - By Stock
|
NYR |
Re:
CHART
|
|
dsa69
|
146 |
28K |
2 |
11:58 |
11:58 |
ASX - By Stock
|
146
|
28K
|
2
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Final Phase I Clinical Trial Patients Dosed and Discharged
|
|
dsa69
|
93 |
22K |
1 |
06/08/25 |
06/08/25 |
ASX - By Stock
|
93
|
22K
|
1
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Final Phase I Clinical Trial Patients Dosed and Discharged
|
|
dsa69
|
93 |
22K |
5 |
06/08/25 |
06/08/25 |
ASX - By Stock
|
93
|
22K
|
5
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
dsa69
|
30 |
7.9K |
1 |
05/08/25 |
05/08/25 |
ASX - By Stock
|
30
|
7.9K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
dsa69
|
30 |
7.9K |
1 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
30
|
7.9K
|
1
|
|
ASX - By Stock
|
TYP |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
dsa69
|
3 |
972 |
1 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
3
|
972
|
1
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Change in substantial holding - M Azzi
|
|
dsa69
|
5 |
1.5K |
2 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
5
|
1.5K
|
2
|
|
ASX - By Stock
|
TYP |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
dsa69
|
3 |
972 |
0 |
01/08/25 |
01/08/25 |
ASX - By Stock
|
3
|
972
|
0
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Change in substantial holding - M Azzi
|
|
dsa69
|
5 |
1.5K |
7 |
31/07/25 |
31/07/25 |
ASX - By Stock
|
5
|
1.5K
|
7
|
|
ASX - By Stock
|
NYR |
Re:
CHART
|
|
dsa69
|
146 |
28K |
4 |
30/07/25 |
30/07/25 |
ASX - By Stock
|
146
|
28K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
dsa69
|
30 |
7.9K |
1 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
30
|
7.9K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
dsa69
|
30 |
7.9K |
0 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
30
|
7.9K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
dsa69
|
30 |
7.9K |
1 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
30
|
7.9K
|
1
|
|
ASX - By Stock
|
TYP |
Re:
TYP Charts
|
|
dsa69
|
52 |
25K |
5 |
28/07/25 |
28/07/25 |
ASX - By Stock
|
52
|
25K
|
5
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
dsa69
|
30 |
7.9K |
3 |
28/07/25 |
28/07/25 |
ASX - By Stock
|
30
|
7.9K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
dsa69
|
30 |
7.9K |
1 |
28/07/25 |
28/07/25 |
ASX - By Stock
|
30
|
7.9K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-Gen PromarkerD test performance results published
|
|
dsa69
|
7 |
2.1K |
0 |
25/07/25 |
25/07/25 |
ASX - By Stock
|
7
|
2.1K
|
0
|
|
ASX - By Stock
|
NYR |
Re:
CHART
|
|
dsa69
|
146 |
28K |
2 |
25/07/25 |
25/07/25 |
ASX - By Stock
|
146
|
28K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-Gen PromarkerD test performance results published
|
|
dsa69
|
7 |
2.1K |
2 |
24/07/25 |
24/07/25 |
ASX - By Stock
|
7
|
2.1K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-Gen PromarkerD test performance results published
|
|
dsa69
|
7 |
2.1K |
0 |
24/07/25 |
24/07/25 |
ASX - By Stock
|
7
|
2.1K
|
0
|
|
ASX - By Stock
|
NYR |
Re:
Ann: NYR Advances Xolatryp Phase IIa Trial in Cardioprotection
|
|
dsa69
|
75 |
15K |
4 |
24/07/25 |
24/07/25 |
ASX - By Stock
|
75
|
15K
|
4
|
|
ASX - By Stock
|
NYR |
Re:
Ann: NYR Advances Xolatryp Phase IIa Trial in Cardioprotection
|
|
dsa69
|
75 |
15K |
3 |
24/07/25 |
24/07/25 |
ASX - By Stock
|
75
|
15K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Chart & SP
|
|
dsa69
|
1 |
541 |
0 |
24/07/25 |
24/07/25 |
ASX - By Stock
|
1
|
541
|
0
|
|
ASX - By Stock
|
NYR |
Re:
Ann: NYR Advances Xolatryp Phase IIa Trial in Cardioprotection
|
|
dsa69
|
75 |
15K |
7 |
23/07/25 |
23/07/25 |
ASX - By Stock
|
75
|
15K
|
7
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Final Phase I Clinical Trial Patients Dosed and Discharged
|
|
dsa69
|
93 |
22K |
9 |
21/07/25 |
21/07/25 |
ASX - By Stock
|
93
|
22K
|
9
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: OxiDx test detects muscle damage in thoroughbred racehorses
|
|
dsa69
|
35 |
8.6K |
0 |
17/07/25 |
17/07/25 |
ASX - By Stock
|
35
|
8.6K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: OxiDx test detects muscle damage in thoroughbred racehorses
|
|
dsa69
|
35 |
8.6K |
2 |
14/07/25 |
14/07/25 |
ASX - By Stock
|
35
|
8.6K
|
2
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Notice of Change of Interests of Substantial Holder - M Azzi
|
|
dsa69
|
57 |
19K |
5 |
08/07/25 |
08/07/25 |
ASX - By Stock
|
57
|
19K
|
5
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: First patent for endometriosis blood test - granted in Japan
|
|
dsa69
|
24 |
9.4K |
2 |
08/07/25 |
08/07/25 |
ASX - By Stock
|
24
|
9.4K
|
2
|
|
ASX - By Stock
|
TYP |
Re:
TYP - Media & News
|
|
dsa69
|
31 |
23K |
5 |
08/07/25 |
08/07/25 |
ASX - By Stock
|
31
|
23K
|
5
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Notice of Change of Interests of Substantial Holder - M Azzi
|
|
dsa69
|
57 |
19K |
1 |
04/07/25 |
04/07/25 |
ASX - By Stock
|
57
|
19K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: AMA grants reimbursement code for Next-Gen PromarkerD test
|
|
dsa69
|
15 |
4.8K |
3 |
04/07/25 |
04/07/25 |
ASX - By Stock
|
15
|
4.8K
|
3
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: AMA grants reimbursement code for Next-Gen PromarkerD test
|
|
dsa69
|
15 |
4.8K |
5 |
03/07/25 |
03/07/25 |
ASX - By Stock
|
15
|
4.8K
|
5
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Notice of Change of Interests of Substantial Holder - M Azzi
|
|
dsa69
|
57 |
19K |
1 |
02/07/25 |
02/07/25 |
ASX - By Stock
|
57
|
19K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Funding boost for precision diagnostics Proteomics Facility
|
|
dsa69
|
8 |
2.5K |
2 |
01/07/25 |
01/07/25 |
ASX - By Stock
|
8
|
2.5K
|
2
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Funding boost for precision diagnostics Proteomics Facility
|
|
dsa69
|
8 |
2.5K |
2 |
01/07/25 |
01/07/25 |
ASX - By Stock
|
8
|
2.5K
|
2
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Notice of Change of Interests of Substantial Holder - M Azzi
|
|
dsa69
|
57 |
19K |
4 |
01/07/25 |
01/07/25 |
ASX - By Stock
|
57
|
19K
|
4
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Funding boost for precision diagnostics Proteomics Facility
|
|
dsa69
|
8 |
2.5K |
1 |
01/07/25 |
01/07/25 |
ASX - By Stock
|
8
|
2.5K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: First patent for endometriosis blood test - granted in Japan
|
|
dsa69
|
24 |
9.4K |
0 |
30/06/25 |
30/06/25 |
ASX - By Stock
|
24
|
9.4K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-gen PromarkerD test system released for predicting DKD
|
|
dsa69
|
20 |
6.3K |
1 |
27/06/25 |
27/06/25 |
ASX - By Stock
|
20
|
6.3K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-gen PromarkerD test system released for predicting DKD
|
|
dsa69
|
20 |
6.3K |
1 |
26/06/25 |
26/06/25 |
ASX - By Stock
|
20
|
6.3K
|
1
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-gen PromarkerD test system released for predicting DKD
|
|
dsa69
|
20 |
6.3K |
0 |
26/06/25 |
26/06/25 |
ASX - By Stock
|
20
|
6.3K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-gen PromarkerD test system released for predicting DKD
|
|
dsa69
|
20 |
6.3K |
3 |
26/06/25 |
26/06/25 |
ASX - By Stock
|
20
|
6.3K
|
3
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Notice of Change of Interests of Substantial Holder - M Azzi
|
|
dsa69
|
57 |
19K |
7 |
25/06/25 |
25/06/25 |
ASX - By Stock
|
57
|
19K
|
7
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-gen PromarkerD test system released for predicting DKD
|
|
dsa69
|
20 |
6.3K |
2 |
25/06/25 |
25/06/25 |
ASX - By Stock
|
20
|
6.3K
|
2
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Phase I Clinical Trial Dosing Update No 4
|
|
dsa69
|
43 |
13K |
6 |
24/06/25 |
24/06/25 |
ASX - By Stock
|
43
|
13K
|
6
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-gen PromarkerD test system released for predicting DKD
|
|
dsa69
|
20 |
6.3K |
0 |
24/06/25 |
24/06/25 |
ASX - By Stock
|
20
|
6.3K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-gen PromarkerD test system released for predicting DKD
|
|
dsa69
|
20 |
6.3K |
0 |
24/06/25 |
24/06/25 |
ASX - By Stock
|
20
|
6.3K
|
0
|
|
ASX - By Stock
|
PIQ |
Re:
Ann: Next-gen PromarkerD test system released for predicting DKD
|
|
dsa69
|
20 |
6.3K |
1 |
23/06/25 |
23/06/25 |
ASX - By Stock
|
20
|
6.3K
|
1
|
|